Semaglutide

REVIEWS from PubMed – March 25, 2024 – Semaglutide (in title) AND Cancer (in title) AND Review

• The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review April 26, 2025
  Background: GLP1 receptor agonists (GLP1-RAs) have become a central component in the treatment of type 2 diabetes mellitus (T2DM) and are gaining prominence in the cardiovascular field. Semaglutide and other GLP1-RA molecules possess cardioprotective properties. Cardiotoxicity, a term used to refer to cardiovascular disease caused by anticancer treatment, is a collection of common and severe […]
  Filippo Biondi
• Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies April 8, 2025
  Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as key agents for weight management, based on their marked efficacy as observed in randomized controlled trials. While still limited, real-world studies on GLP-1RA use in populations with obesity are increasingly available. This narrative review discusses contemporary real-world evidence demonstrating the utilization, clinical and comparative effectiveness, and adverse […]
  Reimar W Thomsen
• A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists April 4, 2025
  CONCLUSIONS: GLP-1 RAs did not increase the incidence of esophageal neoplasms, and there were not probably significant within-class differences in T2DM or obesity treatment. This finding supports the safety of GLP-1 RAs as a therapeutic option for the clinical management of T2DM.
  Qi Wu
• Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss March 27, 2025
  The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly […]
  Lalitha Sundararaman
• Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database March 8, 2025
  CONCLUSION: The study, based on data from the FAERS database, suggests a potential association between GLP-1 receptor agonists and an increased thyroid cancer risk. These findings underscore the importance of further research and continuous safety monitoring when prescribing these medications for obesity management.
  Christophe Abi Zeid Daou
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? March 5, 2025
  Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors and retatrutide is a triple GLP‑1, GIP and glucagon receptor agonist. The GLP‑1 receptor agonists increase insulin release but suppress glucagon release. They slow down the emptying of the […]
  Hubertus Himmerich
• Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past? February 21, 2025
  The prevalence of obesity continues to increase worldwide. Obesity is associated with an increased risk of cardiometabolic and other diseases, reduced quality of life and shortened life expectancy. Highly effective therapies are required to achieve meaningful and sustained weight reduction to prevent, slow or reverse disease associated with obesity. Bariatric surgery is a highly effective […]
  Siehoon Lah
• How 'miracle' weight-loss semaglutide promises to change medicine but can we afford the expense? February 13, 2025
  Obesity is a complex and growing global concern, affecting one in eight individuals and compromising health, quality of life and life expectancy. It carries significant metabolic, cardiovascular, oncological, hepatorenal, skeletal and psychiatric risks, imposing substantial costs on health-care systems. Traditional treatments have often been ineffective or have led to relapse after lifestyle changes. Whereas bariatric […]
  Ralf Weiskirchen
• Nutrient-Stimulating Hormone-Based Therapies for Obesity February 7, 2025
  Obesity is a chronic disease with an increasing worldwide prevalence. Improving obesity is of paramount importance given its association with conditions such as type 2 diabetes, cardiovascular disease, and cancer among others. In the last decade, a new class of highly efficacious medications called nutrient-stimulating hormone (NuSH) therapies has emerged. This article highlights the effectiveness […]
  Cagney Cristancho
• Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map January 26, 2025
  CONCLUSIONS: This umbrella review identified significant beneficial associations between pharmacotherapies and anthropometric measures, lipid profile, blood pressure, glycemic profile, and quality-of-life outcomes in individuals with overweight or obesity. In addition, the umbrella review highlighted safety considerations. The findings affirm the efficacy of the six pharmacotherapies in promoting weight loss in this demographic. Further clinical trials […]
  Ting-Ting Lu
• Letter to the Editor regarding "Semaglutide and cancer: A systematic review and meta-analysis" by Nagendra L et al November 4, 2024
  No abstract
  Yu Xiao
• Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist August 8, 2024
  The use of glucagon-like peptide-1 receptor agonists (GLP-1RA) has experienced rapid growth amidst the obesity epidemic in the United States. While originally developed for glucose control in Type 2 Diabetes Mellitus, the scope of these agents now extends to encompass weight loss and cardiovascular risk reduction. GLP-1RAs have the potential to induce significant weight loss, […]
  Courtney J Riedinger
• The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer May 27, 2024
  Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed […]
  Shahad Sabaawi Ibrahim
• Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity May 14, 2024
  Obesity, a chronic global health problem, is associated with an increase in various comorbidities, such as cardiovascular disease, type 2 diabetes mellitus, hypertension, and certain types of cancer. The increasing global prevalence of obesity requires research into new therapeutic strategies. Glucagon-like peptide-1 receptor agonists, specifically semaglutide and liraglutide, designed for type 2 diabetes mellitus treatment, […]
  Rafael Tamayo-Trujillo
• Obesity pharmacotherapy in older adults: a narrative review of evidence May 6, 2024
  The prevalence of obesity in older adults (people aged >60 years) is increasing in line with the demographic shift in global populations. Despite knowledge of obesity-related complications in younger adults (increased risk of type 2 diabetes, liver and cardiovascular disease and malignancy), these considerations may be outweighed, in older adults, by concerns regarding weight-loss induced […]
  Alex E Henney
• Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review April 27, 2024
  The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and […]
  Catalin Vladut Ionut Feier
• Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia April 11, 2024
  CONCLUSION: Although Semaglutide induced modest weight reductions, it did not offer significant advantages in lowering HbA1C levels compared to other hypoglycemic treatments. These findings suggest the need for further research involving larger and more diverse cohorts to corroborate these findings.
  Yazed AlRuthia
• The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis March 21, 2024
  Despite its considerable and growing burden, there are currently no Food and Drug Administration-approved treatments for metabolic dysfunction-associated steatotic liver disease or its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other agents are in various phases of clinical development for use in MASH; an ideal therapy should reduce liver […]
  Manal F Abdelmalek
• Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review February 12, 2024
  Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective medications for the treatment of type 2 diabetes and obesity. Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for […]
  Ana E Espinosa De Ycaza
• Glucagon-like peptide agonists: A prospective review December 14, 2023
  CONCLUSION: In conclusion, this review underscores the significance of GLP-1RAs, with a specific focus on semaglutide, in the management of type 2 diabetes, obesity, and beyond. By synthesizing information on their mechanisms, pharmacokinetics, efficacy, and safety, this review provides valuable insights into the potential benefits these agents offer, contributing to the ongoing discourse in the […]
  Zamara Mariam